Anti-Human TNFRSF10A Recombinant Antibody (Mapatumumab)

Customer Review

There are currently no Customer reviews or questions for TAB-H48. Click the button above to contact us or submit your feedback about this product.

Emily Walker
16.Jul,23

Ideal for TNFRSF10A Research

The Anti-Human TNFRSF10A Therapeutic Antibody (mapatumumab) has been excellent for our TNFRSF10A research. Its specificity and sensitivity are top-notch, providing clear and reliable results. This antibody has significantly improved the accuracy of our experiments and saved us a lot of troubleshooting time.

John Martinez
12.Dec,22

Effective in Immunoassays

We incorporated this antibody into our immunoassays, and it has been a great asset. The specificity for TNFRSF10A is precise, allowing for accurate detection and analysis. The reliable performance has made it an invaluable tool in our lab.

Sarah Thompson
08.Sep,21

Consistent and Reliable

This antibody has proven to be consistent and reliable in our assays. The high-quality, reproducible results have significantly improved our experiments, making it a crucial part of our research toolkit. The strong affinity and specificity for TNFRSF10A have been particularly beneficial.

Q&As

1. Is the anti-Human TNFRSF10A therapeutic antibody Mapatumumab suitable for use in Western blotting?

   A: Yes, the anti-Human TNFRSF10A therapeutic antibody Mapatumumab (TAB-H48) is suitable for use in Western blotting. It provides specific binding to TNFRSF10A, allowing for reliable detection in Western blot assays.

2. What are the storage recommendations for the anti-Human TNFRSF10A therapeutic antibody Mapatumumab?

   A: The recommended storage condition for the anti-Human TNFRSF10A therapeutic antibody Mapatumumab (TAB-H48) is at -20°C or lower. For short-term storage, it can be kept at 2-8°C. To ensure stability, avoid repeated freeze-thaw cycles.

3. Can the anti-Human TNFRSF10A therapeutic antibody Mapatumumab be used in immunoprecipitation assays?

   A: Yes, the anti-Human TNFRSF10A therapeutic antibody Mapatumumab (TAB-H48) can be used in immunoprecipitation assays. It provides specific binding to TNFRSF10A, enabling the successful precipitation of the target protein from complex mixtures.

4. Is the anti-Human TNFRSF10A therapeutic antibody Mapatumumab effective in ELISA applications?

   A: Yes, the anti-Human TNFRSF10A therapeutic antibody Mapatumumab (TAB-H48) is effective in ELISA applications. It has been validated for use in such assays and provides reliable detection of TNFRSF10A.

5. What is the optimal dilution for using the anti-Human TNFRSF10A therapeutic antibody Mapatumumab in immunofluorescence?

   A: The optimal dilution for using the anti-Human TNFRSF10A therapeutic antibody Mapatumumab (TAB-H48) in immunofluorescence is typically 1:100 to 1:500. It is advisable to perform a dilution series to determine the best working concentration for your specific experimental conditions.

View the frequently asked questions answered by Creative Biolabs Support.

Citations

1. Meyer, Mickael, et al. "Profiling the non-genetic origins of cancer drug resistance with a single-cell functional genomics approach using predictive cell dynamics." Cell systems 11.4 (2020): 367-374. https://doi.org/10.1016/j.cels.2020.08.019
   This study investigates the non-genetic origins of cancer drug resistance through a novel method called fate-seq. Fate-seq links the drug response of single cells to their transcriptomic profiles, enabling the identification of molecular factors that contribute to intrinsic drug resistance. The researchers focused on HeLa cells treated with tumor-necrosis-factor-related apoptosis-inducing ligand (TRAIL) as a proof of concept. The study demonstrated that cell dynamics could distinguish transient transcriptional states, leading to a better understanding of why some cells survive cancer treatments while others do not.
   Creative Biolabs provided critical reagents that were instrumental in validating the research findings. Specifically, the therapeutic antibody mapatumumab (cat# TAB-H48) was supplied by Creative Biolabs, which played a crucial role in demonstrating the increased sensitivity of cells overexpressing SIVA1 to death receptor-mediated apoptosis. This contribution was significant as it helped confirm the potential of SIVA1 as a target gene for enhancing TRAIL-induced cell death.
2. Park, Jong-Sung, et al. "Targeting of dermal myofibroblasts through death receptor 5 arrests fibrosis in mouse models of scleroderma." Nature communications 10.1 (2019): 1128. https://doi.org/10.1038/s41467-019-09101-4
   This research investigates how targeting death receptor 5 (DR5) can reverse fibrosis in scleroderma mouse models. The study reveals that scleroderma progression involves the conversion of resident fibroblasts into myofibroblasts (MFBs) expressing α-smooth muscle actin (α-SMA) with increased capacity to produce collagen and fibrogenic components. The researchers demonstrated that TLY012, an engineered human TNF-related apoptosis-inducing ligand (TRAIL), selectively blocks dermal fibroblast activation and induces DR-mediated apoptosis in α-SMA+ MFBs through upregulated DR5. Significantly, TLY012 reversed established skin fibrosis to near-normal skin architecture in both bleomycin-induced and tight skin-1 (Tsk-1) mouse models of scleroderma.
   Creative Biolabs provided the anti-DR5 agonistic antibody (Conatumumab) and anti-DR4 agonistic antibody (Mapatumumab), which were used to validate the mechanism of DR-mediated apoptosis in myofibroblasts. These antibodies enabled the researchers to demonstrate that DR5, rather than DR4, is predominantly responsible for TLY012-induced apoptosis in activated myofibroblasts. This contribution was essential for establishing that targeting upregulated DR5 in α-SMA+ MFBs represents a viable therapeutic approach for fibrosis in scleroderma, potentially offering a new treatment strategy for this serious autoimmune condition.

Cite This Product

To accurately reference this product in your publication, please use the following citation information:

(Creative Biolabs Cat# TAB-H48, RRID: AB_3112035)

Submit Your Publication

Published with our product? Submit your paper and receive a 10% discount on your next order! Share your research to earn exclusive rewards.

Publications

Our products have been used extensively by scientists all over the world to accelerate their life science research. Here, we present a collection of publications that cite this product.

Park, Jong-Sung, et al. "Targeting of dermal myofibroblasts through death receptor 5 arrests fibrosis in mouse models of scleroderma." Nature communications 10.1 (2019): 1128.

Biosimilar Overview

Please refer to Mapatumumab Overview to learn more about the mechanism of action, clinical projects, and approved drugs of Mapatumumab.

Downloadable Resources

Download resources about recombinant antibody development and antibody engineering to boost your research.

Product Notes

This is a product of Creative Biolabs' Hi-Affi™ recombinant antibody portfolio, which has several benefits including:

• Increased sensitivity
• Confirmed specificity
• High repeatability
• Excellent batch-to-batch consistency
• Sustainable supply
• Animal-free production

See more details about Hi-Affi™ recombinant antibody benefits.

Datasheet

MSDS

COA

To download a Certificate of Analysis, please enter a lot number in the search box below. Note: Certificate of Analysis not available for kit components.

Protocol & Troubleshooting

We have outlined the assay protocols, covering reagents, solutions, procedures, and troubleshooting tips for common issues in order to better assist clients in conducting experiments with our products. View the full list of Protocol & Troubleshooting.

See other products for "Mapatumumab"

Afuco™ Anti-TNFRSF10A ADCC Recombinant Antibody, ADCC Enhanced (AFC-TAB-H48)

This product is an ADCC enhanced antibody produced by our Afuco™ platform. Recombinant human antibody to Human TNFRSF10A. It is an experimental human monoclonal antibody for the treatment of cancer.

DrugMonitor™ Anti-Mapatumumab Antibody (VS-1224-YC710)

Mapatumumab is a fully human agonistic monoclonal antibody targeting TRAIL-R1, currently undergoing clinical trials for cancer treatment, including relapsed or refractory non-Hodgkin's lymphoma (NHL). The DrugMonitor™ Anti-Mapatumumab Antibody (VS-1224-YC710) is an anti-drug antibody (ADA) against Mapatumumab. This drug-based antibody is raised in mice immunized with the Mapatumumab. The anti-Mapatumumab antibody may be used in ELISA, pharmacokinetics (PK), and pharmacodynamics (PD) analyses, or serves as a reference standard in ADA assays. It also is an excellent tool for therapeutic drug monitoring, allowing to evaluate the drug efficacy and determine the drug concentration of the Mapatumumab in samples.

See other products for "TNFRSF10A"

Select a product category from the dropdown menu below to view related products.